NERVGEN PHARMA CORP. Cash And Cash Equivalents
NERVGEN PHARMA CORP. (NGEN) had Cash And Cash Equivalents of CAD 22.07 million as of 2025-12-31, per its 40-F filed 2026-03-31.
Financial Statements › Notes
ifrs-full:CashAndCashEquivalents · last filed 2026-03-31
- 2025-12-31: Cash And Cash Equivalents 22.07M CAD.
- 2024-12-31: Cash And Cash Equivalents 17.27M CAD.
- 2023-12-31: Cash And Cash Equivalents 11.66M CAD.
| Period end | Cash And Cash Equivalents |
|---|---|
| 2025-12-31 | 22.07M CAD 40-F · filed 2026-03-31 |
| 2024-12-31 | 17.27M CAD 40-F · filed 2026-03-31 |
| 2023-12-31 | 11.66M CAD 40-F · filed 2026-03-31 |